Health Quadria commits 25% from $1bn healthcare fund to GCC By Pramod Kumar May 28, 2025, 7:59 AM Quadria Capital Singapore-based private equity company Quadria Capital has invested in Indian eye care chain Maxivision Quadria Capital, a Singapore-based healthcare-focused private equity company, plans to allocate up to a quarter of its latest $1 billion fund to the Gulf Cooperation Council (GCC). “In the GCC, we intend to deploy capital across healthcare infrastructure such as hospitals and clinics, biopharma, diagnostics and digital health,” Quadria Capital partner Sunil Thakur told AGBI in an emailed statement. He said that nearly 15 percent of the fund was raised from GCC-based financial institutions, development organisations, corporates and family offices, without disclosing any names. The GCC healthcare sector is undergoing rapid growth, fuelled by population expansion, rising chronic diseases and bold government reforms, he said. Healthcare expenditure in the GCC is forecast to reach $159 billion a year by 2029, a compound annual growth rate of almost 8 percent from 2024, according to a report by Alpen Capital. Quadria’s fund III raised a total of $1.07 billion in commitments, exceeding its original target of $800 million. An additional $300 million co-investment capacity is anticipated during the investment phase, which will increase the total committed capital to $1.3 billion. The latest fundraising round was 60 percent larger than its previous $600 million fund in 2020. The company has deployed 40 percent of the fund in Indian healthcare companies such as Aragen Life Sciences, dialysis chain NephroPlus and eye care network Maxivision. Gulf healthcare battling staff shortages as demand rises Digital health innovators expand in Saudi Arabia Affordable healthcare in the GCC: a prescription for profit Two new investments in southeast Asia are expected soon, with Gulf investors expected to participate in co-investment opportunities. Quadria Capital manages over $4 billion in assets across 27 investments in south and southeast Asia, including India, Vietnam, Indonesia, Malaysia and Singapore. This month Mubadala Investment Company, Abu Dhabi’s $330 billion sovereign wealth fund, launched a dedicated life sciences unit as part of a broader strategy to boost domestic pharmaceutical production, improve healthcare resilience and support the UAE’s economic diversification efforts. Abu Dhabi last month launched a health, endurance, longevity and medicine (Helm) cluster, which it is hoped will contribute AED94 billion ($26 billion) to the emirate’s GDP in the next two decades and create 30,000 new jobs. Register now: It’s easy and free AGBI registered members can access even more of our unique analysis and perspective on business and economics in the Middle East. Why sign uP Exclusive weekly email from our editor-in-chief Personalised weekly emails for your preferred industry sectors Read and download our insight packed white papers Access to our mobile app Prioritised access to live events Register for free Already registered? Sign in I’ll register later Register now: It’s easy and free AGBI registered members can access even more of our unique analysis and perspective on business and economics in the Middle East. Why sign uP Exclusive weekly email from our editor-in-chief Personalised weekly emails for your preferred industry sectors Read and download our insight packed white papers Access to our mobile app Prioritised access to live events Register for free Already registered? Sign in I’ll register later
